Cargando…

Psoriasis, COVID‐19 and shielding

Linked Article: Mahil et al. Br J Dermatol 2021; 185:80–90.

Detalles Bibliográficos
Autores principales:	Becher, G., Burden, A.D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239873/ https://www.ncbi.nlm.nih.gov/pubmed/33951179 http://dx.doi.org/10.1111/bjd.20055

Ejemplares similares

Universal masking in hospitals in the COVID-19 era: Is it time to consider shielding?
por: Advani, Sonali D., et al.
Publicado: (2020)

COVID-19 and medical liability: Italy denies the shield to its heroes
por: d'Aloja, Ernesto, et al.
Publicado: (2020)

Treatment of severe psoriasis with infliximab
por: Leman, JA, et al.
Publicado: (2008)

The “Criminal Shield”: Criminal Liability for Healthcare Professionals during the COVID-19 Pandemic
por: Bolino, Giorgio, et al.
Publicado: (2023)

Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times
por: Brownstone, Nicholas D., et al.
Publicado: (2020)

Defamation lawsuits: academic sword or shield?
por: Hall‐Lipsy, Elizabeth, et al.
Publicado: (2017)

Construction of Two Box-Like Head-and-Face Shields by Japanese Origami Folding for Use During the COVID-19 Pandemic
por: Tago, Masaki, et al.
Publicado: (2020)

‘I exist because of we’: shielding as a communal ethic of maintaining social bonds during the COVID-19 response in Ethiopia
por: Seifu Estifanos, Abiy, et al.
Publicado: (2020)

Closed Gateways — Can Neuroprotectants Shield the Retina in Glaucoma?
por: Velpandian, Thirumurthy
Publicado: (2012)

Bulky glycocalyx shields cancer cells from invasion-associated stresses
por: Piplani, Niyati, et al.
Publicado: (2023)

CD7 CAR: sword and shield
por: Velasquez, M. Paulina, et al.
Publicado: (2022)

Predicting treatment success with biologics in psoriasis
por: van den Reek, J.M.P.A.
Publicado: (2019)

Putting together the psoriasis puzzle: an update on developing targeted therapies
por: Johnson-Huang, Leanne M., et al.
Publicado: (2012)

Psoriasis & cardiovascular morbidity: The missing links?
por: Ganguly, Satyaki, et al.
Publicado: (2017)

Clinical Goals and Barriers to Effective Psoriasis Care
por: Strober, Bruce E., et al.
Publicado: (2018)

Comparison of COVID-19 outcomes among shielded and non-shielded populations
por: Jani, Bhautesh D., et al.
Publicado: (2021)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Temporary exacerbation of pre-existing psoriasis and eczema in the context of COVID-19 messenger RNA booster vaccination: A case report and review of the literature
por: Phuan, Crystal Zhen Yu, et al.
Publicado: (2021)

Clinical and trichoscopic aspects of scalp psoriasis: commentary to ‘Clinical and trichoscopic features in various forms of scalp psoriasis’ by F. Bruni et al.
por: Lacarrubba, F.
Publicado: (2021)

Atopic Dermatitis and Psoriasis are Diagnosed Clinically and Treated Empirically
por: Aggarwal, Pushkar, et al.
Publicado: (2022)

Systemic treatments for psoriasis: not another network meta‐analysis!
por: Leonardi‐Bee, Jo, et al.
Publicado: (2022)

Biomarkers in atopic dermatitis and psoriasis—a Delphi‐based guide through the jungle?
por: Fehr, D., et al.
Publicado: (2022)

Targeting immune cell trafficking and vascular endothelial cells in psoriasis
por: Young, Kelly Z., et al.
Publicado: (2023)

Living with Psoriasis Vulgaris and Multi-Treatment Failure: A Patient and Dermatologist Perspective
por: Spencer, Riley K., et al.
Publicado: (2023)

Commentary: A clinician should know about systemic psoriasis and eye
por: Balamurugan, M S, et al.
Publicado: (2022)

Data‐driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine
por: van der Schoot, L. S., et al.
Publicado: (2021)

Critical weaknesses in shielding strategies for COVID-19
por: Smith, Cameron A., et al.
Publicado: (2022)

Is heat shock protein 90 inhibition a relevant treatment strategy for psoriasis?
por: Bachelez, Hervé
Publicado: (2022)

Exploring the Clinical Features, Immunopathogenesis and Approach to Diagnosis for Generalized Pustular Psoriasis [Podcast]
por: Bhutani, Tina, et al.
Publicado: (2023)

Exploring the Clinical Assessment, Guidelines, and Options for the Treatment of Generalized Pustular Psoriasis [Podcast]
por: Song, Eingun James, et al.
Publicado: (2023)

266: Physiotherapy during the COVID-19 pandemic: Support for the shielding patient by the shielding physiotherapist
por: Carson, J., et al.
Publicado: (2021)

Development of clinical diagnostic criteria for plaque psoriasis in children: an electronic Delphi consensus study with the International Psoriasis Council
por: Burden‐Teh, E., et al.
Publicado: (2019)

Psoriasis Vulgaris Successfully Treated with Goeckerman Treatment at Home: A Patient and Physician’s Experience
por: Reddy, Vidhatha, et al.
Publicado: (2020)

Anti‐interleukin‐17A for pityriasis rubra pilaris: catching the psoriasis biologic wave
por: Balak, Deepak M.W., et al.
Publicado: (2022)

The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
por: Papp, Kim A., et al.
Publicado: (2021)

CDK4/6 and diffuse intrinsic pontine glioma - Evaluate at diagnosis?
por: Becher, Oren J.
Publicado: (2019)

manufacture of protective masks/shields COVID-19
por: Fichet, Jacques Herve, et al.
Publicado: (2020)

Ethics of participation and social inclusion of older persons in research: lessons learned from the COVID-19 pandemic in Singapore
por: Maulod, Ad, et al.
Publicado: (2022)

Secukinumab without the initial loading dose in the treatment of plaque‐type psoriasis – a simplified dosing regimen at the expense of efficacy?
por: Aichelburg, M.C., et al.
Publicado: (2019)

Topical therapy of psoriasis: Where do we stand?
por: Thappa, DM, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9p04a82at1di4nnfuuld5hne4c